Abstract
Introduction

!
The HIV-1 pandemic continues to spread worldwide. It would be desirable to have a protective vaccine, but despite massive effort over the past 20 years such a vaccine remains elusive. Live attenuated vaccines have provided the most robust protection against viral challenge in animal models, but they are considered unsafe for human use (1-3). Moreover, the immune correlates of protection by live attenuated vaccines remain undefined, hampering the design of safer vaccines (4). Sterilizing protection can be achieved in nonhuman primates by passively immunizing with neutralizing Ab (NAb). Infusion of the NAb b12 directed against the CD4-binding site (CD4BS) on gp120 inhibited vaginal infection with SHIV in a dose-dependent manner (13, 14) . Other passive immunization studies using broadly active NAb such as 2F5 or 2G12 also showed protection against SHIV challenge (15) (16) (17) (18) . Passive immunization with the b12 NAb 2-18 h after viral challenge did not block HIV-1 infection, showing that the time window of NAb to provide protection against HIV-1 acquisition is limited (19) . Thus, preexisting NAb can provide sterilizing protection, but inducing them with current vaccines has been unsuccessful.
Formulating antigens in adjuvants can improve their immunogenicity. Commonly used adjuvants that stimulate the innate immune system include agonists of pattern recognition receptors such as are toll-like receptors, as well as inorganic molecules, emulsion surfactants, or other carrier molecules that have immune stimulating properties (20) . An alternative, more specific approach is the use of costimulatory host-derived proteins that activate specific immune cells. The adjuvant effects of such costimulatory molecules can be increased by covalently linking them directly to the antigen of choice (21) (22) (23) (24) .
One immune molecule that can serve as an adjuvant in vaccines is the granulocytemacrophage colony-stimulating factor (GM-CSF). This cytokine is produced by fibroblasts, activated T lymphocytes, macrophages, tumor, endothelial, mesothelial and epithelial cells and functions as a hematopoietic growth factor. GM-CSF is secreted during various types of inflammation to stimulate proliferation and prevents apoptosis of various immune cells (25) , such as antigen-presenting cells (APCs) (26) . Its activity is mediated by the GM-CSF receptor (GMR) that is composed of a specific α-GMR domain and a commonly shared βc subunit that is also a part of the IL-3 and IL-5 cytokine receptor. Signaling is mediated by formation of a hexameric complex consisting of two GM-CSF molecules and the four receptor subunits.
Ultimately, two of these GM-CSF-GMR hexamers can dimerize to form a dodecameric complex. Depending on the GM-CSF concentration and the nature of the ligand-receptor complex, GM-CSF can induce different downstream signaling cascades. Low picomolar concentrations of the cytokine promote cell survival, whereas higher GM-CSF concentrations can stimulate cell proliferation.
Here we investigated whether GM-CSF embedded within the HIV-1 trimeric gp140 protein can augment Env-specific immune responses. The rationale for integrating GM-CSF within the Env protein was to simultaneously activate immune cells that are targeted by the antigen, resulting in a selective and specific augmentation of the antigen-specific immune response. To do this, the first and second variable loop domain (V1V2) of Env was replaced by the GM-CSF. The resulting chimeric EnvGM-CSF was folded properly and had GM-CSF activity in vitro. Mice immunized with the chimeric protein had stronger Env-specific Ab and T cell responses than those given unmodified Env protein. Embedding cytokine domains is therefore useful for enhancing the immunogenicity of HIV-1 Env-based vaccines.
Materials and methods
!
Plasmid construction
The pPPI4 plasmid (Progenics Pharmaceuticals, Tarrytown, NY) encoding stabilized SOSIP.R6-IZ-H8 gp140 (Env) using optimized codons has been described elsewhere (27) (28) (29) (30) (31) .
The Env construct is based on the subtype B, CCR5 primary isolate JR-FL and is shown in supplemented with 10% heat-inactivated fetal calf serum (FCS; HyClone, Perbio, Etten-Leur, the Netherlands), MEM nonessential amino acids (0.1 mM; Invitrogen, Breda, the Netherlands) and penicillin/streptomycin (P/S; both at 100 U/ml). TZM-bl cells, which express the HIV-1 receptors CD4, CCR5 and CXCR4, were cultured and maintained in DMEM supplemented with 10% FCS, 0.1 mM MEM and P/S. These cells contain the luciferase gene under control of the HIV-1 LTR promoter and were used to measure HIV-1 neutralization. TF-1 cells, a gift from Paul Coffer (Universiteit Utrecht), were cultured in RPMI 1640 (Invitrogen) with 10% FCS, supplemented with 50 U/ml of rhGM-CSF (Schering-Plough). Splenic lymphocytes were maintained in RPMI 1640 (Invitrogen) supplemented with 10% FBS, HEPES, glutamine, sodium pyruvate, P/S, MEM and 2-mercaptoethanol.
!
Env production
293T cells were transiently transfected (32) with plasmids expressing recombinant Env using linear polyethylenimine (PEI, MW 25000; Polysciences Europe GmbH, Eppelheim, Germany) or Lipofectamine 2000 transfection reagent according to standard manufacturer's protocol (Invitrogen). Briefly, plasmid DNA was diluted in one-tenth of the final culture volume of DMEM and mixed with PEI (0.15 mg/ml final concentration). After incubation for 20 min, the DNA-PEI mix was added to the cells for 4 h before being replaced with normal culture medium. Env-containing supernatants were harvested 48 h after transfection and frozen in aliquots.
! ! ! gp140 trimer ELISA
Env trimer ELISAs were performed as described previously (29, 30) . Supernatants containing His-tagged Env gp140 proteins were diluted 1:3 in TBS, 10% FCS and added for 2 h to preblocked nickel-nitrilotriacetic (Ni-NTA) HisSorb (Ni-NTA) 96-well plates (Qiagen). After three washes using TSM (20 mM Tris, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2), serially diluted polyclonal HIV-Ig, Env specific mAbs, DC-SIGN-Fc or CD4-IgG2 in TSM, 5% BSA was then added for 2 h, with or without 1 µg/ml sCD4, followed by three washes with TSM, 0.05% Tween 20. HRP-labeled goat anti-human immunoglobulin G (0.2 µg/ml; Jackson Immunoresearch) was used as secondary Ab and the absorption at 450 nm was measured after the colorimetric reaction was stopped using H2SO4.
!
gp120 ELISA
Anti-gp120 Ab titers were measured by ELISA (30) . In short, Microlon 96-well plates (Greiner Bio-One, Alphen aan den Rijn, the Netherlands) were coated with anti-gp120 Ab D7324 (10 µg/ml). The plates were washed twice with TBS and residual protein-binding sites were blocked with 2% skim milk powder (Sigma-Aldrich) in TBS for 30 min. gp120 from transiently transfected 293T cells was added to D7324-coated wells for 2 h at room temperature. Mice serum serially diluted in 20% sheep serum (Biotrading, Mijdrecht, the Netherlands), 2% skim milk powder in TBS was applied for 2 h. gp120-specific mouse IgG was detected with HRP-labeled goat anti-mouse IgG (Jackson Immunoresearch), used at 1:5000 (0.2 µg/ml), followed by colorimetric detection. Endpoint titers were calculated using Graphpad Prism version 5.03 by determining the serum dilution at which the OD450 signal was three times above the OD450 background signal obtained without mice sera.
!
SDS-PAGE, blue native PAGE and western blotting
SDS-PAGE and western blotting were performed as previously described (30) . Env was detected using the primary mAb PA1 (0.2 µg/ml) and a secondary HRP-labeled goat antimouse IgG (1:5000 dilution) followed by Western Lightning ECL solution (PerkinElmer Life Sciences). Blue native PAGE was carried out as previously reported (30) . Briefly, purified protein samples or cell culture supernatants were diluted with an equal volume of a buffer containing 100 mM MOPS, 100 mM Tris with HCl, pH 7.7, 40% glycerol, and 0.1% Coomassie blue, immediately prior to loading onto a NuPAGE 4-12% bis-Tris gel (Invitrogen). Typically, gel electrophoresis was performed for 2 h at 150 V (~0.07A) using 50 mM MOPS, 50 mM Tris, pH 7.7, as running buffer. 
!
V3 peptide competition assay
Pooled sera from five Envwt-or EnvmGM-CSF-immunized mice were incubated with a mix of three peptides (Env V3-1: NNNTRKSIHIGPGRA, Env V3-2: SIHIGPGRAFYTTGE, Env V3-3: GRAFYTTGEIIGDIR (30 µg/ml each)) overlapping the V3 sequence of HIV-1 JR-FL, or with an unrelated peptide (QAPKPRKQ; 90 µg/ml) for 1 h at room temperature. The peptide-serum mixtures were then tested in the HIV-1 neutralization assay. To control for nonspecific inhibition by the peptides, we also performed neutralization assays using mAb b12 (6 µg/ml) in the presence or absence of the three V3 peptides. 
T cell responses
The number of splenic T cells from immunized mice was determined by LSR-II flow cytometry (BD Biosciences) using standard cell surface staining protocols. Data was analyzed using FlowJo software. In short, prior to staining, Fc receptors were blocked using an antimouse CD16/CD32 antibody (clone 2.4G2). Cell surface staining of TCRβ, CD3, CD4 and 
!
Modeling chimeric gp120hGM-CSF trimers
Structural models for the gp120-hGM-CSF within a trimeric spike were generated as follows.
The trimeric configuration of gp120 in an unliganded spike was obtained by fitting the b12-bound conformation of the gp120 HxBC2 core (PDB ID:2NY7; (33)) into the cryoelectron tomography density of unliganded HIV-1 BaL strain using the program Chimera (34, 35) .
RosettaDesign (36, 37) was used to thread the sequence of JR-FL core gp120 onto the 2NY7 gp120 structure from residue 83 to 492. The structure of hGM-CSF (PDB ID:2GMF, chain A, residues 9-122 (38)) was inserted at the V1V2 stem between residues 127 and 195 (gp120 2NY7 numbering), flanked by Gly-Ser-Gly (GSG) linkers on both sides. The conformations of the connecting segments and the rigid body orientation of hGM-CSF relative to the gp120 trimer were modeled using RosettaRemodel (P.H. and W.R.S., manuscript in preparation).
Briefly, the backbones for the connecting segments (2NY7 residues 112-127 and 195-212 plus the GSG linkers) were generated using an ab initio fragment insertion protocol (39), cycliccoordinate descent was used to maintain proper backbone connectivity (40, 41) , and rebuilt segments were further optimized by cyclic-coordinate descent refine (40, 41) and side-chain repacking. Modeling of hGM-CSF on the gp120 V1V2 stem bound to the b12 Fab fragment was carried out to determine functional steric constraints in the model. Disulfide bonds in the V1V2 (2NY7 residues 119-205 and 126-196) were approximated by C-C distance constraints.
The V3 loop was left truncated as in 2NY7. Possible isoforms (~1000) of EnvhGM-CSF were generated and models (~100) with the lowest energy state were further filtered for (a) clashfree binding of b12, CD4 (33) 
!
Results
!
Design of an HIV-1 Env trimer with an embedded GM-CSF domain
To generate a trimeric HIV-1 Env immunogen that could be targeted to immune cells and simultaneously stimulate immune activation, we deleted the V1V2 domain of gp120 and replaced it with almost the complete sequence of the GM-CSF cytokine. We used the stabilized SOSIP.R6-IZ gp140 protein backbone, hereafter called Env (27, 28, 30, 31) . The mouse or human GM-CSF (mGM-CSF or hGM-CSF) sequence was inserted after the second cysteine bridge in the V1V2 stem between amino acids 127 and 195. To facilitate flexibility at the junctions between GM-CSF and Env, Gly-Ser-Gly linkers were added to the N and C termini of the GM-CSF sequence (Fig. 1A and 1B) . In total, 120 and 116 amino acids were introduced for hGM-CSF and mGM-CSF, respectively, at the expense of 65 amino acids of the V1V2 domain.
! Chimeric EnvhGM-CSF is expressed efficiently and forms trimers
To determine whether the chimeric EnvhGM-CSF protein was produced and folded properly, we transiently transfected 293T cells with gp140 (Envwt), gp140 lacking the V1V2 domain (Env∆V1V2) (29) and EnvhGM-CSF. The expression of all constructs was determined using SDS-PAGE and western blotting (Fig. 2, left panel) . The expression of EnvhGM-CSF was slightly lower than Envwt. The EnvhGM-CSF protein had an apparent molecular mass of 150 kDa, Envwt of 140 kDa and Env∆V1V2 of 120 kDa, consistent with the expected sizes (Fig. 2, left panel) .
The Envwt, Env∆V1V2 and EnvhGM-CSF proteins were all predominantly expressed as trimers when analyzed by blue native PAGE (Fig. 2, right panel) , showing that replacing the V1V2 domain with hGM-CSF did not markedly affect trimer formation or stability.
! Chimeric EnvhGM-CSF is recognized by neutralizing antibodies
To determine whether EnvhGM-CSF had an antigenic structure comparable with Envwt, we used a trimer ELISA and assessed its binding to a panel of Abs and receptor mimics (30) .
Polyclonal Ig from pooled HIV-positive patient sera (HIV-Ig) bound similarly to Envwt, EnvhGM-CSF and Env∆V1V2 (Fig. 3A) . The 2F5 mAb, directed to the gp41 epitope located far from the GM-CSF insertion, also bound identically to the three proteins (Fig. 3A) . Similar findings were made using the human DC-SIGN-Fc protein and the 2G12 mAb that both recognize oligomannose N-glycans on gp120 (Fig. 3B) .
We then tested the conformation of Env epitopes closer to the GM-CSF insertion. V3 mAb 39F recognized the three Env proteins equally well, as did CD4-IgG2, a receptor mimic for CD4 (Fig. 3C) . NAbs VRC01 and b12 against discontinuous epitopes associated with the CD4-binding site (CD4BS) recognized EnvhGM-CSF (Fig. 3C ), but the binding was subtly less efficient compared with that to Envwt (by 2-fold for VRC01, 4-fold for b12). Thus, the CD4BS on EnvhGM-CSF is intact, but the accessibility and/or conformation of the b12 and, to a lesser extent, VRC01 epitopes is subtly altered by the replacement of the V1V2 domain by GM-CSF.
Page ! 40 CD4 binding induces a conformational change in Env involving rearrangement of the V1V2 domain, which exposes the coreceptor binding site and the overlapping CD4-induced (CD4i) epitopes. In the absence of CD4, the CD4i epitope mAb 17b, 48d and 412d bound poorly to Envwt and EnvhGM-CSF but efficiently to Env∆V1V2, as expected (Fig. 3D, left panels) .
Adding soluble CD4 substantially increased the binding of these mAb to Env∆V1V2 and especially to Envwt, but binding to EnvhGM-CSF was improved only modestly (Fig. 3D, right   panels) . Hence the presence of GM-CSF in the V1V2 region either limits the accessibility of the CD4i epitopes or blocks the conformational changes that expose them. Collectively, the Env conformational analyses show that the overall antigenic structure of EnvhGM-CSF is similar to that of Envwt, but some epitopes located close to the insertion site are affected by the GM-CSF insertion.
Page ! 41 
The GM-CSF domain of chimeric EnvhGM-CSF is functional
To probe the integrity of the GM-CSF domain, we performed an ELISA using a conformation-dependent neutralizing GM-CSF mAb (Fig. 4A) . The EnvhGM-CSF protein was efficiently recognized by this mAb, whereas Envwt and Env∆V1V2 were not. Hence the GM-CSF domain embedded within the Env backbone assumes a similar conformation as native GM-CSF.
The functional activity of the inserted GM-CSF domain was tested using TF-1 cells, which require GM-CSF signaling for proliferation. The number of living TF-1 cells was measured by flow cytometry after a 5-day culture with 293T cell supernatant containing the EnvhGM-CSF, Envwt or Env∆V1V2 protein. Supernatant from untransfected 293T cells was used as a negative control, and rhGM-CSF protein, diluted in 293T culture medium, as a positive control. TF-1 cells exposed to EnvhGM-CSF medium proliferated in a dose-dependent manner, as did cells stimulated with authentic rhGM-CSF (Fig. 4B) . In contrast, apoptosis was observed in TF-1 cell cultures treated with Envwt, Env∆V1V2, or the mock medium. The hGM-CSF protein tethered to the Env backbone was not as potent as soluble rhGM-CSF at stimulating TF-1 cell proliferation. The maximal response of EnvhGM-CSF, extrapolated from the curve trend, was calculated at ~32000 living cells. rhGM-CSF had an maximal response of 41000 living TF-1 cells. Based on the half-maximal response levels for the secreted EnvGM-CSF and the authentic rhGM-CSF, we estimated the GM-CSF activity of EnvGM-CSF. The halfmaximal stimulation response of EnvhGM-CSF-containing supernatant was reached at a 3-fold dilution, whereas the half-maximal response to rhGM-CSF occurred at 1.9 U/ml. EnvhGM-CSF was therefore estimated to have a GM-CSF activity equivalent to 5.7 U/ml.
Page ! 42 
Model of an EnvhGM-CSF trimer
Based on the atomic structure of hGM-CSF (43), the structures of gp120 in complex with either b12, CD4 (33), or VRC01 (42), a gp120 trimer model (44) , and additional information provided by the antigenicity and functional data (Fig. 3 and Fig. 4) , we generated a structural model of the EnvhGM-CSF trimer. Because of the flexibility of the linkers, GM-CSF can be modeled on the gp120 core in multiple orientations. Three symmetric EnvhGM-CSF trimers ("down", "side", and "up") are depicted in Fig. 5 to illustrate the diversity of potential low energy conformations. We note that hGM-CSF will likely sample a range of conformations around and between the "down", "side" and "up" conformations, and that the orientation of GM-CSF may not be symmetrical in the three gp120 subunits. All the models in epitope is restricted by GM-CSF, as observed with the CD4i Ab-binding data (Fig. 3) .
!
EnvmGM-CSF induces enhanced Env-specific Ab responses in mice
To test whether incorporating the GM-CSF protein within Env would improve Env-specific immune responses, we immunized mice with plasmids expressing Env, with or without embedded murine GM-CSF, according to the schedule present in Fig. 6A . In addition we immunized mice with plasmids encoding the Env protein (again, with or without embedded mGM-CSF) coupled to mouse BAFF (mBAFF) or mouse CD40L (mCD40L). BAFF and CD40L are costimulatory molecules that were linked C-terminally to the Env to provide an Page ! 43 Figure 5 . Three different models of EnvhGM-CSF trimers. hGM-CSF (magenta) is shown in up (top panels), side (middle panels) or down (lower panels) orientation attached to gp120 (cyan). The models were generated using Chimera (35) , RosettaDesign (37) and RosettaRemodel as described under "Materials and methods" and rendered using PyMOL (version 1.3, Schrödinger, LLC).
additional stimulus for immune activation. The mice were immunized on days 0, 14, 28 and 42, and the gp120-specific IgG response was measured by ELISA. The gp120-specific Ab titer for mice immunized with plasmids encoding Env-mBAFF or Env-mCD40L was not significantly greater than found with Env (Student's t-test) (Fig. 6B) . Thus, the Env-mBAFF and Env-mCD40L constructs did not improve the immune response against Env whether mGM-CSF was present or not. To increase the statistical power of subsequent analyses, we therefore pooled all of the mice groups that received Env and all of the groups given Env containing embedded mGM-CSF, irrespective of the additional presence of mBAFF or mCD40L sequences (Fig. 6C) . Anti-Env Ab were detected at low levels after the first boost on day 14. The endpoint titers from Env-and EnvmGM-CSF-immunized mice were significantly different after the second boost on day 28. The corresponding titers for the EnvmGM-CSF group were 3-fold higher than for the Env control group (471 versus 
EnvmGM-CSF induces improved Env-specific T helper responses
GM-CSF is known to activate a variety of cells but not B cells, implying that the enhanced Ab response was probably mediated indirectly through other cell types. We therefore investigated the Env-specific T cell response in spleen cells from mice immunized with Env or EnvmGM-CSF, focusing on the induction of cytokines that are important for B cell responses. Spleens were harvested on day 56 and their cytokine production profile was measured by restimulating the splenocytes with gp120 protein or anti-CD3 compared with a mock stimulation. gp120-induced IL-2 secretion was 37 pg/ml for Env-immunized mice and 54 pg/ml for EnvmGM-CSF mice (p=0.06) (Fig. 7A) . IL-2 secretion in response to anti-CD3 Ab could not be detected (Fig. 7B) . IL-4 production by splenic T cells from the EnvmGM-CSF group was 6-fold higher than the Env group (41 pg/ml versus 7 pg/ml, p<0.0001; Fig. 7A ), and IL-4 secretion induced by the anti-CD3 Ab was also higher (147 pg/ml versus 75 pg/ml, p=0.02; Fig. 7B ).
Env-specific IL-5 production was similarly increased in the EnvmGM-CSF group compared to the Env group (45 pg/ml versus 14 pg/ml, p=0.02), whereas IL-5 secretion in response to the Page ! 45 anti-CD3 Ab was comparable. We could not detect Env-specific IL-21 production, but production of this cytokine in response to the anti-CD3 mAb was significantly higher in the EnvGM-CSF-immunized mice than in the Env group (63 pg/ml versus 23 pg/ml, p=0.003).
There were no differences in IFN-γ or IL-10 production between the Env and EnvmGM-CSF immunized mice in response to either gp120 or anti-CD3 mAb restimulation.
Collectively, these results indicate that EnvmGM-CSF is better than Envwt at inducing Env-specific T cell responses to supply T help for B cells. The cytokine data are thus consistent with the enhanced Ab responses.
!
EnvmGM-CSF induces enhanced neutralizing antibody responses
The mouse model is not an ideal system to induce NAb responses against HIV-1 (45).
Nonetheless, we tested whether the sera from mice immunized with Envwt or EnvmGM-CSF DNA constructs contained Ab with neutralizing activity against HIV-1. Day 42 sera from 5 mice of each of the Envwt and EnvmGM-CSF groups were pooled and tested in a single-cycle neutralization assay using TZM-bl reporter cells. Ab neutralization was tested on the highly sensitive tier 1 isolate SF162 and the more resistant tier 2 isolate, JR-FL. The pooled sera had no neutralization activity against JR-FL (data not shown). Sera from both groups of mice were active against SF162, but the 50% titer was significantly higher for the pooled EnvmGM-CSF sera (368 versus 110, p<0.0001; Fig. 8A ). Although neutralization of the sensitive SF162 has little relevance to the development of a useful vaccine, the results confirm the outcome of the Ab assays and show that replacing the V1V2 domain with GM-CSF improves the Ab response to Env.
Neutralization of SF162 by immune sera is predominantly mediated by V3-specific Abs (46) . To assess whether EnvmGM-CSF-immunized mice also predominantly generate V3-directed NAb, we performed a V3 peptide competition assay. Mice sera of day 42 were preincubated with an excess of three overlapping V3 peptides to inhibit the neutralization by V3-directed NAbs (Fig. 8B) . Envwt sera inhibited SF162 infection by 51% and the preincubation with V3 peptides restored infection to ~100%, while addition of an unrelated control peptide did not restore infection. These results show that SF162 neutralization by Envwt sera was mediated exclusively by anti-V3 specificities. In contrast EnvmGM-CSF sera reduced SF162 infection by 72% and adding V3 peptides only partially reversed the inhibition (to 59%), implying that NAbs with specificities other than V3 were present. As a control, we showed that neutralization of SF162 by NAb b12 against the CD4BS was not affected by addition of the V3 peptides (Fig. 8B) . Thus, replacing the V1V2 domain with GM-CSF may divert the Ab response away from V3 and towards other epitopes on Env that may be more relevant to broadly active neutralization.
!
Discussion
!
To improve the immunogenicity of HIV-1 Env vaccines, we constructed a chimeric gp140 trimer in which the V1V2 region of gp120 was replaced by the GM-CSF cytokine. We selected GM-CSF because it has a well defined adjuvant activity and usage in humans has been shown to be safe. We found that the chimeric EnvGM-CSF protein was more immunogenic than the unmodified Env trimers in mice, with improvements of both Ab and T helper responses.
Adjuvants can be more powerful when they are coupled directly to antigen rather than when the two components are supplied as a mixture. For example, conjugating oligodeoxynucleotides (CpG ODN) to a Gag protein enhances the magnitude and quality of Gag-specific T cell responses (21) . In earlier studies, the immune response was improved by linking HIV-1 Env antigens directly to costimulatory molecules such as C3d, TNF-α, Fmslike tyrosine kinase receptor-3 ligand, or Fas Ligand (FasL) (23, 24, (47) (48) (49) . The advantage of Page ! 47 (A) The percentage of SF162 infectivity in the absence or presence of serial dilutions of pooled sera from the Envwt or EnvmGM-CSF mice was measured in a single-cycle infectivity assay using TZM-bl cells. Significance was determined using a two-way analysis of variance test. (B) The percentage SF162 infectivity in the presence of pooled sera diluted 20 times was measured in the absence or presence of a mixture of three overlapping V3 peptides or of an unrelated peptide. To assess whether the V3 peptide pool had nonspecific effects, we measured whether they affected neutralization by b12. chimeric adjuvant fusion proteins over chemically linked adjuvant antigen complexes is that the former can be produced easily directly from DNA at a constant antigen to adjuvant ratio.
Instead of linking the costimulatory adjuvant molecules such as FasL or TNF-α to the N or C termini of Env, we replaced the V1V2 loop domain with the costimulatory GM-CSF molecule. The V1V2 loop was selected because this region can be deleted from Env without compromising the structure and, to some extent, the function of the protein (29, 50) . Flexible linkers were added at the Env-GM-CSF junctions to enable the cytokine to fold independently into a native structure and to reduce the possibility of a steric clash between the two components of the chimera. The chimeric EnvGM-CSF protein was expressed efficiently in 293T cells as a secreted trimer (Fig. 2) . Ab binding to most Env epitopes was very similar to that seen with the corresponding, unmodified Env, with the exception of the b12 and CD4i epitopes close to the GM-CSF insertion site, which were affected modestly (Fig. 3) .
Although GM-CSF embedded into Env was functional, it did not stimulate TF-1 cell proliferation to the same level as recombinant, soluble GM-CSF (Fig. 4) . It is possible that, despite the use of flexible linkers, GM-CSF binding to its receptor is partially blocked by proximal regions of Env. Alternatively, one GM-CSF molecule may be able to bind to the GMR normally, but formation of a ternary dodecameric complex is affected, limiting downstream signaling (51) (52) (53) . In theory, binding of Env to CD4 on TF-1 cells could counteract the proliferative activity of GM-CSF (54). This explanation however seems unlikely, since addition of Envwt did not affect the activation of TF-1 cells by rhGM-CSF (data not shown).
The serum half-life of recombinant GM-CSF is short, varying from 0.9 to 2.5 h (55, 56) . This factor could adversely influence the adjuvant effect of GM-CSF, particularly when the immunogen and cytokine are either mixed or transcribed from separate plasmids.
How fusion of Env with GM-CSF affects the half-life of both proteins requires further study.
Chimeric proteins such as those described here have not been described before, but GM-CSF has been used as an adjuvant in vaccine studies with a variety of results. Codelivering GM-CSF in peptide-based vaccines, either as recombinant protein or plasmid DNA, augments HIV-1-specific T cell responses to various extents (57) (58) (59) . Co-delivery of rhesus macaque GM-CSF expressed from DNA with Gag, Pol, and Env DNA followed by an MVA boost results in higher avidity anti-Env Ab in rhesus macaques (60) . Mice immunized with a bicistronic plasmid encoding gp120 and GM-CSF have stronger gp120-specific CD4 + T cell responses than mice immunized with gp120 and GM-CSF on two separate plasmids (61) . Hence, the method of GM-CSF co-delivery affects the outcome of the immune response.
The timing of GM-CSF co-delivery also affects the outcome of the response. In one study, delivery of a GM-CSF plasmid prior to vaccination with a plasmid encoding a vaccine antigen yielded a Th2-type response, whereas GM-CSF delivery after vaccination with the antigen resulted in a Th1-type response. Both Th1 and Th2 responses are generated when GM-CSF and antigen are administered simultaneously (62) . Although Ab to recombinant human GM-CSF protein (rhGM-CSF) arose when it was used in a human vaccine trial, they caused neither adverse hematologic events nor a loss of GM-CSF function (58).
We initially chose to introduce GM-CSF as a costimulatory molecule, but other However, some limitations need to be recognized when incorporating cytokines into the Env backbone. First, the length and molecular weight of the inserted protein should preferably be similar to the replaced V1V2 region, which spans 60 to 80 amino acids, including 6 glycans (in total ~20 kDa). Moreover, the N and C termini of the folded cytokine preferably should be close together such that the bulk of the protein protrudes away from the 
